A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer's disease. The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nearly 30 LOAD susceptibility loci2-12 are known, and risk is significantly polygenic13.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“Recent sequencing studies identified a number of genes that have rare variants associated with AD9-11,18-24.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“The NH2-terminal APP A673T(Icelandic) mutation, however, makes APP a less favorable substrate for 𝛃 -secretase, resulting in decreased A 𝛃 production (299).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [299]
In the citing paper
“This observation is also true for the rare variant p.A673T (rs63750847) in APP, which was identified in Icelanders and was shown to have a strong protective effect against age-related cognitive decline as well as AD [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
In the citing paper
“The p.A673T variant was observed in control subjects aged over 85 years at a frequency of 0.45%, which is higher than that seen in AD patients [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
A new multipoint method for genome-wide association studies by imputation of genotypes
Marchini, J., Howie, B., Myers, S., McVean, G., & Donnelly, P. (2007) · Nature Genetics · doi:10.1038/ng2088 · Cited by 2,609
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
MDS Cognitive Performance Scale(C)
Morris, J. N., Fries, B. E., Mehr, D. R., Hawes, C., Phillips, C., Mor, V., & Lipsitz, L. A. (1994) · Journal of Gerontology · doi:10.1093/geronj/49.4.m174 · Cited by 1,810
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Cited by
Items 301–400 of 1,008
Hoogmartens, J., Cacace, R., & Van Broeckhoven, C. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12155 · Cited by 104
Ahn, H. J., Glickman, J. F., Poon, K. L., Zamolodchikov, D., Jno-Charles, O. C., Norris, E. H., & Strickland, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131751 · Cited by 100
“However, numerous studies still support the hypothesis that A plays an important role in the pathogenesis of AD (Tanzi and Bertram, 2005; Jonsson et al., 2012).”
BackgroundApolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer’s disease
Dorey, E., Chang, N., Liu, Q. Y., Yang, Z., & Zhang, W. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1422-z · Cited by 116
“More recently, a particular APP mutation found in Icelanders has been shown to cause decreased APP processing and Aβ production, providing protection against AD and cognitive decline([12]).”
Ryan, P., Patel, B., Makwana, V., Jadhav, H. R., Kiefel, M., Davey, A., Reekie, T. A., Rudrawar, S., & Kassiou, M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00185 · Cited by 100
Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer’s disease
Xian, X., Pohlkamp, T., Durakoglugil, M. S., Wong, C. H., Beck, J. K., Lane-Donovan, C., Plattner, F., & Herz, J. (2018) · eLife · doi:10.7554/elife.40048 · Cited by 98
Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome
Startin, C. M., Hamburg, S., Hithersay, R., Al‐Janabi, T., Mok, K. Y., Hardy, J., LonDownS Consortium, & Strydom, A. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.009 · Cited by 97
“The recent failure of clinical drug trials directed at amyloid, including anti-amyloid antibodies and BACE inhibition, has been a considerable disappointment given the genetic evidence suggesting reduced BACE cleavage over a lifetime protects against AD [42].”
BackgroundCellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071884 · Cited by 97
“On the contrary, inheritance of a missense mutation in APP, that decreases the production and aggregation of Aβ, protects against AD and age-related cognitive decline [41].”
BackgroundTEC Monitoring by Using Satellite Positioning Systems
Jakowski, N. (1996) · elib (German Aerospace Center) · Cited by 117
Resting State fMRI and Improved Deep Learning Algorithm for Earlier Detection of Alzheimer’s Disease
Guo, H., & Zhang, Y. (2020) · IEEE Access · doi:10.1109/access.2020.3003424 · Cited by 110
“By measuring the connectivity of the brain network in some brain regions, a network focused on each resting-state operations may be built and the loss of brain function between AD and healthy patients may be assessed [9], [10].”
BackgroundGenetics of Alzheimer’s Disease
Ridge, P. G., Ebbert, M. T. W., & Kauwe, J. S. K. (2013) · BioMed Research International · doi:10.1155/2013/254954 · Cited by 92
Advances in Alzheimer’s Disease Drug Development
Rafii, M. S., & Aisen, P. S. (2015) · BMC Medicine · doi:10.1186/s12916-015-0297-4 · Cited by 94
“Recent genetic evidence shows that mutations near the beta-secretase cleavage site that prevent such cleavages lead to decreased production of A β and are, indeed, protective against developing AD dementia, despite ApoE4 status [10].”
Association of Alzheimer's disease GWAS loci with MRI markers of brain aging
Chauhan, G., Adams, H. H. H., Bis, J. C., Weinstein, G., Yu, L., Töglhofer, A. M., Smith, A. V., van der Lee, S. J., Gottesman, R. F., Thomson, R., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.028 · Cited by 98
Garbuz, D. G., Zatsepina, O. G., & Evgen’ev, M. B. (2021) · Molecular Biology · doi:10.1134/s002689332104004x · Cited by 106
Walker, L. C. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3025 · Cited by 174
“The promise of prevention is underscored by the protective effects of the A673T mutation in APP, which diminishes Aβ production throughout life and lowers the risk of AD [48].”
BackgroundUnderstanding the roles of mutations in the amyloid precursor protein in Alzheimer disease
Hunter, S., & Brayne, C. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.218 · Cited by 94
Measuring heritable contributions to Alzheimer’s disease: polygenic risk score analysis with twins
Karlsson, I. K., Escott-Price, V., Gatz, M., Hardy, J., Pedersen, N. L., Shoai, M., & Reynolds, C. A. (2022) · Brain Communications · doi:10.1093/braincomms/fcab308 · Cited by 92
“tion analyses suggesting that it predicted higher cognitive status scores among nursing home residents.(48) Moreover, gene–environment interplay may increase estimates of genetic influences.”
Kimura, A., Hata, S., & Suzuki, T. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.744722 · Cited by 95
“Substitution of Val for Ala(673) (A673V) is pathogenic, resulting in elevated production of A , whereas substitution of Thr at the same position (A673T, the Icelandic mutation) is protective (23, 25).”
BackgroundResultUsing population isolates in genetic association studies
Hatzikotoulas, K., Gilly, A., & Zeggini, E. (2014) · Briefings in Functional Genomics · doi:10.1093/bfgp/elu022 · Cited by 94
Zempel, H., & Mandelkow, E.-M. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0064-1 · Cited by 96
“Conversely, a mutation that decreases the aggregation capacity of Aβ is protective of AD [33].”
Anti-amyloid Aggregation Activity of Natural Compounds: Implications for Alzheimer’s Drug Discovery
Bu, X., Rao, P. P. N., & Wang, Y. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9301-4 · Cited by 103
“a crucial role in the pathogenesis of AD [9].”
BackgroundCebers, G., Alexander, R. C., Haeberlein, S. B., Han, D., Goldwater, R., Ereshefsky, L., Olsson, T., Ye, N., Rosen, L., Russell, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160701 · Cited by 91
Blood will out: vascular contributions to Alzheimer’s disease
Strickland, S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97509 · Cited by 91
“One would need to look for protective genes; such a study has been done, and it uncovered an APP mutation that confers protection against AD (122).”
Rosenman, D. J., Wang, C., & García, A. E. (2015) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b09379 · Cited by 98
Kanatsu, K., Morohashi, Y., Suzuki, M., Kuroda, H., Watanabe, T., Tomita, T., & Iwatsubo, T. (2014) · Nature Communications · doi:10.1038/ncomms4386 · Cited by 111
“The RIPA extract was used for quantitation of Ab by ELISA (Human/Rat beta-Amyloid (40) ELISA Kit (#294-62501, WAKO Pure Chemical Industries) and Human/Rat b-Amyloid (42) ELISA Kit, High Sensitivity (#292-64501, WAKO Pure Chemical Industries) and also analysed by SDS-PAGE and western blots.”
MethodKell, D. B., & Pretorius, E. (2016) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2016.08.006 · Cited by 96
Alzheimer’s disease – the journey of a healthy brain into organ failure
Golde, T. E. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00523-1 · Cited by 88
Neuropathological approaches to cerebral aging and neuroplasticity
Jellinger, K. A., & Attems, J. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.1/kjellinger · Cited by 90
“Cognition and its decline associated with brain aging also seems to be variable and possibly open to modifications.1 Studies in humans and animal models suggest that age-related cognitive decline is more likely to be associated with alterations in synaptic connectivity than with neuronal loss and white matter changes.…”
BackgroundInfluentialRevitalizing Psychiatric Therapeutics
Hyman, S. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.181 · Cited by 99
“These pathways and protein networks can, in turn, be exploited to select or to help validate molecular targets for potential therapies (Jonsson et al, 2012).”
BackgroundLiu, Q., Waltz, S., Woodruff, G., Ouyang, J., Israel, M. A., Herrera, C., Sarsoza, F., Tanzi, R. E., Koo, E. H., Ringman, J. M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2482 · Cited by 91
The missing link in the amyloid cascade of Alzheimer’s disease – Metal ions
Tiiman, A., Palumaa, P., & Tõugu, V. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.023 · Cited by 104
Bukhari, H., Glotzbach, A., Kolbe, K., Leonhardt, G., Loosse, C., & Müller, T. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.05.005 · Cited by 88
The Prion-Like Properties of Amyloid-β Assemblies: Implications for Alzheimer's Disease
Walker, L. C., Schelle, J., & Jucker, M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024398 · Cited by 104
“…position 2 of Ab (A673Taccording to APP770 numbering) reduces the production of Ab following bsecretase cleavage (Jonsson et al. 2012) and also lowers the propensity of Ab to aggregate (Benilova et al. 2014); the A673T mutation thereby also lessens the risk of developing AD (Jonsson et al. 2012).”
InfluentialGenome-scale neurogenetics: methodology and meaning
McCarroll, S. A., Feng, G., & Hyman, S. E. (2014) · Nature Neuroscience · doi:10.1038/nn.3716 · Cited by 87
In search of low-frequency and rare variants affecting complex traits
Panoutsopoulou, K., Tachmazidou, I., & Zeggini, E. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt376 · Cited by 85
Aβ propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease
Condello, C., & Stöehr, J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.014 · Cited by 86
Tsatsanis, A., Wong, B. X. W., Gunn, A. P., Ayton, S., Bush, A. I., Devos, D., & Duce, J. A. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0762-0 · Cited by 98
Ratan, Y., Rajput, A., Maleysm, S., Pareek, A., Jain, V., Pareek, A., Kaur, R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051398 · Cited by 82
“By boosting A β synthesis and decreasing the A β 40/A β 42 ratio, dysregulated APP function likely aids in the etiology of AD [73].”
BackgroundDrug development for Alzheimer’s disease: Review
Lao, K., Ji, N., Zhang, X., Qiao, W., Tang, Z., & Gou, X. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2018.1474361 · Cited by 86
“[23] Jonsson T, Atwal JK, Steinberg S, et al.”
BackgroundDel Prete, D., Rice, R. C., Rajadhyaksha, A. M., & D'Adamio, L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.733626 · Cited by 86
“A polymorphism in APP that reduces APP processing protects from sporadic Alzheimer disease (AD) (1).”
BackgroundBACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology
Peters, F., Salihoglu, H., Rodrigues, E., Herzog, E., Blume, T., Filser, S., Dorostkar, M., Shimshek, D. R., Brose, N., Neumann, U., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1804-9 · Cited by 89
“In agreement with this notion, relatively modest but sustained reduction of Aβ levels by 40% results in five- to sevenfold reduced risk of developing AD [46].”
Molecular Mechanisms of Synaptotoxicity and Neuroinflammation in Alzheimer’s Disease
Marttinen, M., Takalo, M., Natunen, T., Wittrahm, R., Gabbouj, S., Kemppainen, S., Leinonen, V., Tanila, H., Haapasalo, A., & Hiltunen, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00963 · Cited by 88
NLRP3 polymorphisms are associated with late-onset Alzheimer's disease in Han Chinese
Tan, M., Yu, J., Jiang, T., Zhu, X., Wang, H.-F., Zhang, W., Wang, Y., Jiang, W., & Tan, L. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.10.002 · Cited by 90
Pitt, J., Wilcox, K. C., Tortelli, V., Diniz, L. P., Oliveira, M. S., Dobbins, C., Yu, X.-W., Nandamuri, S., Gomes, F. C. A., DiNunno, N., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-06-0416 · Cited by 84
“This is strongly supported by the discovery of the Icelandic A673T mutation in APP; this mutation decreases Aβ production and protects carriers against AD onset (Jonsson et al., 2012).”
BackgroundSaul, A., Sprenger, F., Bayer, T. A., & Wirths, O. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.003 · Cited by 88
Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease
Allen, G. I., Amoroso, N., Anghel, C., Balagurusamy, V., Bare, C. J., Beaton, D., Bellotti, R., Bennett, D. A., Boehme, K. L., Boutros, P. C., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.006 · Cited by 89
“Recently discovered disease-associated rare variants have larger effect sizes than common variants and confer 2-to 5-fold greater risk or protection in carriers relative to the general population [28–30].”
BackgroundShifting paradigms: The central role of microglia in Alzheimer’s disease
Schwabe, T., Srinivasan, K., & Rhinn, H. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104962 · Cited by 84
Brody, D. L., Jiang, H., Wildburger, N., & Esparza, T. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0293-3 · Cited by 87
“The most compelling genetic evidence favoring a key role for Aβ or another related amyloid-precursor protein (APP) fragment can be briefly summarized as follows: mutations that cause increases in amyloid precursor protein (APP) production or alterations in cleavage favoring certain products lead to early onset dementi…”
BackgroundChen, J., Wang, J., Yin, B., Pang, L., Wang, W., & Zhu, W. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00348 · Cited by 85
The Links between Cardiovascular Diseases and Alzheimer's Disease
Leszek, J., Вячеславовна, М. Е., Belousov, D. M., Koutsouraki, E., Szczechowiak, K., Kobusiak−Prokopowicz, M., Mysiak, A., Diniz, B. S., Somasundaram, S. G., Kirkland, C. E., et al. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200729093724 · Cited by 115
“Although mutations are mostly negative, Icelandic mutation has been described as the only protective mutation in AD, as it diminishes Aβ [40, 41].”
BackgroundPersonalized Sequencing and the Future of Medicine: Discovery, Diagnosis and Defeat of Disease
Esplin, E. D., Oei, L., & Snyder, M. P. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.117 · Cited by 100
Initiative, F. T. A. D. N., Ridge, P. G., Karch, C. M., Hsu, S., Arano, I., Teerlink, C. C., Ebbert, M. T. W., Gonzalez Murcia, J. D., Farnham, J. M., Damato, A. R., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0486-1 · Cited by 83
“Recently, several possibly functional, rare variants with large protective [9, 10] and risk effects [11–13] have been identified for AD in APP, APOE, PLD3, and TREM2 using novel study designs.”
BackgroundCai, W., Li, L., Sang, S., Pan, X., & Zhong, C. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-022-00985-9 · Cited by 83
“Notably, the APP mutant A673T reduced Aβ by 40%–50% [102, 103] in a laboratory study and by ~ 28% in human plasma [104], which is thought to be protective against AD.”
BackgroundThe Alzheimer’s Disease Mitochondrial Cascade Hypothesis: A Current Overview
Swerdlow, R. H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221286 · Cited by 93
β-Amyloid Prions and the Pathobiology of Alzheimer’s Disease
Watts, J. C., & Prusiner, S. B. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a023507 · Cited by 82
“…pathological changes in the brain (Wisniewski et al. 1985); (4) mutations in the APP gene that decrease Aβ production are protective against AD (Jonsson et al. 2012); and (5) mutations in the genes encoding the presenilin proteins increase the relative abundance of pro-amyloidogenic Aβ…”
Brodney, M. A., Beck, E. M., Butler, C. R., Barreiro, G., Johnson, E. F., Riddell, D. R., Parris, K. D., Nolan, C. E., Fan, Y., Atchison, K. P., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00191 · Cited by 86
Tharp, W. G., & Sarkar, I. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-290 · Cited by 82
“cing the formation of Aβ was identified [10].”
BackgroundAmyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
Marr, R. A., & Hafez, D. M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00187 · Cited by 83
“This hypothesis is bolstered by the discovery of a protective mutation in APP in an Icelandic population that reduces BACE1 proteolysis and lowers Aβ levels (Jonsson et al., 2012).”
Polygenic Analysis of Late-Onset Alzheimer’s Disease from Mainland China
Jiao, B., Liu, X., Zhou, L., Wang, M. H., Zhou, Y., Xiao, T., Zhang, W., Sun, R., Waye, M. M. Y., Tang, B., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0144898 · Cited by 82
“Until now, only two variants were identified to protect individuals away from AD: rs63750847-A in APP and APOEε2 genotype [32].”
BackgroundEarly Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Lemche, E. (2018) · Current Genomics · doi:10.2174/1389202919666171229145156 · Cited by 87
Multi-ancestry meta-analysis and fine-mapping in Alzheimer’s disease
Lake, J., Solsberg, C. W., Kim, J. J., Acosta‐Uribe, J., Makarious, M. B., Li, Z., Levine, K. S., Heutink, P., Alvarado, C. X., Vitale, D., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02089-w · Cited by 90
“All SNPs in the 99% credible sets were annotated with VEP (http:// grch37.ensembl.org/Homo_sapiens/Tools/VEP) using default criteria to select one block of annotation per variant (Table S4).”
MethodGenomic and Epigenomic Insights into Nutrition and Brain Disorders
Dauncey, M. (2013) · Nutrients · doi:10.3390/nu5030887 · Cited by 79
“For example, recent studies have identified: a low-frequency variant in the amyloid-β precursor protein (APP) that protects against Alzheimer’s disease and age-related cognitive decline [31], a common variant conferring risk of psychosis [32], common SNPs and rare copy number variants (CNVs) that may confer risk to an…”
BackgroundFanutza, T., Del Prete, D., Ford, M. J., Castillo, P. E., & D’Adamio, L. (2015) · eLife · doi:10.7554/elife.09743 · Cited by 83
“In humans, a polymorphism in APP that reduces APP processing protects from sporadic Alzheimer’s disease (AD) and normal aging-dependent cognitive decline (De Strooper and Voet, 2012, Jonsson et al., 2012).”
BackgroundMethodCaselli, R. J., Beach, T. G., Knopman, D. S., & Graff-Radford, N. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.011 · Cited by 81
“Furthermore, although most APP variants are pathogenic, one has been described that actually protects against AD by reducing b-secretase 1 cleavage and so Ab production.(44)”
Walter, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.704981 · Cited by 80
“Interestingly, a mutation within the A domain of APP has also been shown be associated with a decreased risk for AD (60).”
BackgroundTen Challenges of the Amyloid Hypothesis of Alzheimer’s Disease
Kepp, K. P. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160550 · Cited by 81
“The protective A2T mutation [125] has been widely used as a showcase of the amyloid hypothesis [101], and its lower produced A (cid:2) levels fit well to quantitative gain of function as the protective alternative to the Swedish mutation and A2V [126].”
Kerridge, C., Belyaev, N. D., Nalivaeva, N. N., & Turner, A. J. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12680 · Cited by 80
“Indeed, a very recent report identifying the first human mutation in APP (A673T) that protects against AD and age-related cognitive decline provides an independent proof of principle of the amyloid hypothesis (Jonsson et al. 2012).”
BackgroundHow next-generation sequencing is transforming complex disease genetics
Kilpinen, H., & Barrett, J. C. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.10.001 · Cited by 98
Naia, L., Shimozawa, M., Bereczki, E., Li, X., Liu, J., Jiang, R., Giraud, R., Leal, N. S., Pinho, C. M., Berger, E., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02289-4 · Cited by 79
Hori, Y., Takeda, S., Cho, H., Wegmann, S., Shoup, T. M., Takahashi, K., Irimia, D., Elmaleh, D. R., Hyman, B. T., & Hudry, E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.586602 · Cited by 78
“Autosomal dominantly inherited mutations in APP that lead to enhanced A generation (12) or increased oligomerization (13) cause AD, whereas a recently reported APP mutation has been shown to decrease A by 40% and to be protective (14, 15).”
BackgroundResultInfluentialSerneels, L., T’Syen, D., Perez-Benito, L., Theys, T., Holt, M. G., & De Strooper, B. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00399-z · Cited by 78
Application of CRISPR/Cas9 in Alzheimer’s Disease
Lu, L., Xi, Y., Cai, Y., Sun, M., & Yang, H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.803894 · Cited by 91
BACE2, a conditional β-secretase, contributes to Alzheimer’s disease pathogenesis
Wang, Z., Xu, Q., Cai, F., Liu, X., Wu, Y., & Song, W. (2019) · JCI Insight · doi:10.1172/jci.insight.123431 · Cited by 79
“Recently, a missense mutation in the APP gene was shown to suppress Aβ production and reduce the risk of AD (3, 6, 7).”
BackgroundHampel, H., Schneider, L. S., Giacobini, E., Kivipelto, M., Sindi, S., Dubois, B., Broich, K., Nisticò, R., Aisen, P. S., & Lista, S. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995637 · Cited by 75
“Although there is yet no clinical evidence for this, the recent finding that a genetically confirmed decrease in Ab production by 40% provides evident protection against AD [166] further supports the idea that the timing of an Abtargeted intervention may be important for clinical response.”
BackgroundNongpiur, M. E., Khor, C. C., Jia, H., Cornes, B. K., Chen, L.-J., Qiao, C., Nair, K. S., Cheng, C., Xu, L., George, R. J., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004089 · Cited by 82
Buggia-Prévot, V., Fernandez, C. G., Udayar, V., Vetrivel, K. S., Elie, A., Roseman, J., Sasse, V. A., Lefkow, M., Meckler, X., Bhattacharyya, S., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.12.006 · Cited by 77
“It is extremely important to understand details of BACE1 trafficking and processing of APP in neurons because a single amino acid substitution adjacent to the BACE1 cleavage site of APP, which significantly reduces BACE1 cleavage and thus Ab peptide generation in cultured cells, has been recently found to protect agai…”
BackgroundColombo, A., Wang, H., Kuhn, P.-H., Page, R., Kremmer, E., Dempsey, P. J., Crawford, H. C., & Lichtenthaler, S. F. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.08.011 · Cited by 62
“, 2010) and with a novel APP mutation (expressed in HEK293 cells), which blocks BACE1 cleavage and reduces the risk for Alzheimer's disease (Jonsson et al., 2012).”
BackgroundResultSiddiqui, S. S., Springer, S. A., Verhagen, A., Sundaramurthy, V., Alisson-Silva, F., Jiang, W., Ghosh, P., & Varki, A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.799346 · Cited by 76
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease
Aisen, P. S. S., Vellas, B. J., & Hampel, H. J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3842-c1 · Cited by 81
Schönherr, C., Bien, J., Isbert, S., Wichert, R., Prox, J., Altmeppen, H., Kumar, S., Walter, J., Lichtenthaler, S. F., Weggen, S., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0084-5 · Cited by 76
“The mutation lies at position two of Aβ (Aβ-A/T) and has been shown to reduce BACE-1 mediated Aβ generation by 40 % using synthetic peptides as substrates [28].”
ADGC, A. D. N. I., Chapuis, J., Flaig, A., Grenier-Boley, B., Eysert, F., Pottiez, V., Deloison, G., Vandeputte, A., Ayral, A.-M., Mendes, T., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1652-z · Cited by 75
“This hypothesis was recently strengthened by the discovery of a rare APP mutation that lowered both Aβ peptide production and the AD risk [12].”
BackgroundDetecting At-Risk Alzheimer’s Disease Cases
Fladby, T., Pålhaugen, L., Selnes, P., Waterloo, K., Bråthen, G., Hessen, E., Almdahl, I. S., Arntzen, K.-A., Auning, E., Eliassen, C. F., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170231 · Cited by 74
Jakubowski, J. M., Orr, A. A., Le, D. A., & Tamamis, P. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00561 · Cited by 75
Amyloid Cascade Hypothesis for the Treatment of Alzheimer’s Disease: Progress and Challenges
Wu, T., Lin, D., Cheng, Y., Jiang, S., Riaz, M. W., Fu, N., Mou, C., Ye, M., & Zheng, Y. (2022) · Aging and disease · doi:10.14336/ad.2022.0412 · Cited by 73
“A673T, a coding mutation of the APP gene, could inhibit the β-cleavage of APP and consequently reduce the level of Aβ formation by approximately 40% [18].”
BackgroundInsulin resistance, neuroinflammation, and Alzheimer’s disease
Najem, D., Bamji-Mirza, M., Chang, N., Liu, Q. Y., & Zhang, W. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0050 · Cited by 74
New evolutions in the BACE1 inhibitor field from 2014 to 2018
Hsiao, C.-C., Rombouts, F., & Gijsen, H. J. M. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.049 · Cited by 74
Genomic View of Bipolar Disorder Revealed by Whole Genome Sequencing in a Genetic Isolate
Georgi, B., Craig, D. W., Kember, R. L., Liu, W., Lindquist, I. E., Nasser, S., Brown, C. D., Egeland, J. A., Paul, S. M., & Bućan, M. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004229 · Cited by 86
“A combination of WGS with dense SNP genotypes that allow long-range haplotype phasing has been successfully utilized to identify variants that influence risk for sick sinus syndrome, gout, gliomas, ovarian cancer and Alzheimer’s disease [58–62].”
BackgroundThe Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review
Freudenberg-Hua, Y., Li, W., & Davies, P. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00108 · Cited by 74
“Thus, in addition to the Mendelian disease presentation of EOAD, a substantial proportion of EOAD cases fall into the category of sporadic and genetically complex disease.”
BackgroundInfluentialMolecular Genetics of Neurodegenerative Dementias
Hinz, F. I., & Geschwind, D. H. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a023705 · Cited by 73
“Interestingly, a protective variant (A676T) in APP has recently been identified for AD in the Icelandic population (Jonsson et al. 2012).”
BackgroundUnderstanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73
“In a recent study, Jonsson and colleagues [58] noted that a specific mutation in APP, which previously had been identified to be located close to the b-secretase site [59], made it a worse substrate for BACE1 and correspondingly was associated with lower Ab production and lower risk of AD.”
BackgroundJohnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Genomics and Functional Genomics of Alzheimer's Disease
Kamboh, M. I. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01152-0 · Cited by 73
“Ala673Thr mutation is associated with reduced production of amyloidogenic Aβ peptides by about 40%, and the generated Aβ is less prone to aggregation [32, 35].”
BackgroundTreatment strategies in Alzheimer’s disease: a review with focus on selenium supplementation
Aaseth, J., Alexander, J., Bjørklund, G., Hestad, K. A., Dušek, P., Roos, P. M., & Alehagen, U. (2016) · BioMetals · doi:10.1007/s10534-016-9959-8 · Cited by 79
“against cognitive decline (Jonsson 2013). APP is Biometals (2016) 29:827–839 829”
Andrew, R. J., Fernandez, C. G., Stanley, M., Jiang, H., Nguyen, P., Rice, R. C., Buggia-Prévot, V., De Rossi, P., Vetrivel, K. S., Lamb, R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708568114 · Cited by 69
Paris, D., Ait-Ghezala, G., Bachmeier, C., Laco, G., Beaulieu-Abdelahad, D., Lin, Y., Jin, C., Crawford, F., & Mullan, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608091 · Cited by 73
“Interestingly, a coding mutation found in the APP gene resulting in a reduction of A production is protective against AD and cognitive decline in the elderly (6, 7) further supporting the view that A is a key culprit in the pathobiology of AD.”
BackgroundMelchiorri, D., Merlo, S., Micallef, B., Borg, J.-J., & Dráfi, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1196413 · Cited by 70
“The so-called Aβ hypothesis of AD is mainly supported by genetic data as all known mutations linked to familial AD affect the production or aggregation tendency of Aβ, and AD-protective mutation variants of the Aβ precursor protein, APP, have been reported (Jonsson et al., 2012).”
BackgroundJoshi, Y. B., & Praticò, D. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00436 · Cited by 84
“However, more recent clinical data have also found mutations in the APP gene that are protective and reduce AD risk (Jonsson et al., 2012, 2013).”
BackgroundAmyloid precursor protein (APP) A673T mutation in the elderly Finnish population
Kero, M., Paetau, A., Polvikoski, T., Tanskanen, M., Sulkava, R., Jansson, L., Myllykangas, L., & Tienari, P. J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.09.017 · Cited by 72
Söllvander, S., Nikitidou, E., Gallasch, L., Zyśk, M., Söderberg, L., Sehlin, D., Lannfelt, L., & Erlandsson, A. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1134-4 · Cited by 70
Talwar, P., Sinha, J., Grover, S., Rawat, C., Kushwaha, S. S., Agarwal, R., Taneja, V., & Kukreti, R. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9390-0 · Cited by 80
Biomarkers in pharmacology and drug discovery
Anderson, D. C., & Kodukula, K. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.026 · Cited by 75
Metadata
- Authors
- Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jönsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., & Stefansson, K.
- Affiliations
- Genentech (US)
- deCODE Genetics (Iceland) (IS)
- University of Oslo (NO)
- Karolinska Institutet (SE)
- University of Helsinki (FI)
- ORCID
- Venue
- Nature
- Published
- 2012-07-11
- Volume
- 488
- Issue
- 7409
- Pages
- 96-99
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2154755614
- Cited by
- 1,738
- References
- 26
- Citations by year
- 2026: 56 · 2025: 72 · 2024: 93 · 2023: 94 · 2022: 70 · 2021: 120 · 2020: 134 · 2019: 107 · 2018: 134 · 2017: 145 · 2016: 155 · 2015: 166 · 2014: 173 · 2013: 154 · 2012: 60
- FWCI
- 119.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL-102924, HL-102925, HL 103010, HL-102926)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, amyloid precursor protein, APP gene, protective genetic variants, cognitive decline in older adults, amyloid plaques, β-cleavage, amyloidogenic peptides, genetic risk, Icelandic population
- MeSH terms
- Aging, Alleles, Alzheimer Disease, Cognition, Cognition Disorders, Humans, Mutation, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Amyloid Precursor Protein Secretases, HEK293 Cells, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.